BZP, whose abuse profile compared with ADHD treatment drugs is not documented enough to establish any correlation, nonetheless lacks the potency to qualify for Schedule I but was deemed a serious enough concern for control under Schedule III, allowing Health Canada to suspend its sale, but not that of its less potent derivatives, pending further assessment. MBZP remains uncontrolled in Canada as of 2015.
BZP, whose abuse profile relative to ADHD treatment drugs is insufficiently documented to confirm any correlation, lacks the potency required for Schedule I classification yet was deemed a serious enough concern to be regulated under Schedule III. This allowed Health Canada to suspend its sale but not that of its less potent derivatives pending further assessment. MBZP remains unregulated in Canada as of 2015.